Nationwide Children's News Releases
Viewing: 41-50 of 99 | All
Jul 20, 2016
AveXis Receives U.S. FDA Breakthrough Therapy Designation for AVXS-101 Gene Replacement Therapy for Spinal Muscular Atrophy Type 1
AveXis, Inc., (Nasdaq:AVXS) a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced the U.S.
Jul 01, 2016
Dean Lee, MD, PhD, to Lead Cell Therapy Programs at Nationwide Childrens Hospital and The Ohio State University Comprehensive Cancer Center
Dean Lee, MD, PhD, has been named the director of the Cellular Therapy and Cancer Immunotherapy Program for Nationwide Children’s Hospital’s Division of Hematology/Oncology/BMT and Center for Childhood Cancer and Blood Diseases. Dr.
Feb 29, 2016
Loss of MHCI in Motor Neurons Leads to ALS Astrocyte Toxicity
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a devastating progressive neurodegenerative disease that results in the death of motor neurons, the nerve cells that control muscles.
Dec 01, 2015
Nationwide Children's Hospital Researcher, Mark Peeples, PhD, Elected as AAAS Fellow
Mark Peeples, PhD, principal investigator in the Center for Vaccines and Immunity at Nationwide Children’s Hospital, has been elected a Fellow in the American Association for the Advancement of Science (AAAS). Dr.
Jul 08, 2015
Dr. John Barnard Expands Leadership Role At Nationwide Children's Hospital And The Ohio State University
John A. Barnard, MD, President of The Research Institute at Nationwide Children’s Hospital, has been appointed both Chair of the Department of Pediatrics at The Ohio State University College of Medicine and Chief of Pediatrics at Nationwide Children’s Hospital.
May 07, 2015
Cure SMA Provides Additional Funding for Promising Spinal Muscular Atrophy Research at Nationwide Childrens Hospital
Cure SMA, the leading organization dedicated to the treatment and cure of spinal muscular atrophy (SMA), recently provided an additional $445,000 grant toward a gene therapy for SMA at Nationwide Children’s Hospital.
Apr 03, 2015
Cure Duchenne to Host a Webinar on Duplication Research for Duchenne Muscular Dystrophy with Dr. Kevin Flanigan from Nationwide Childrens Hospital on April 6
NEWPORT BEACH, Calif. -- CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, will host an “Update on Duplication Mutation Research for Duchenne Muscular Dystrophy” webinar with Dr.
Aug 11, 2014
Discovery of New Form of Dystrophin Protein Could Lead to Therapy for Some DMD Patients
Scientists have discovered a new form of dystrophin, a protein critical to normal muscle function, and identified the genetic mechanism responsible for its production. Studies of the new protein isoform, published online Aug.
May 27, 2014
Nationwide Childrens Hospital receives $10 million gift from the Nationwide Insurance Foundation establishing the Nationwide Pediatric Innovation Fund
Nationwide Children’s Hospital today announced that it has received a $10 million gift from the Nationwide Insurance Foundation. The gift will establish the Nationwide Pediatric Innovation Fund at Nationwide Children’s Hospital, supporting pediatric research and innovative projects
Mar 26, 2014
Study Identifies Key Player in Motor Neuron Death in Lou Gehrigs Disease
Amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease, is marked by a cascade of cellular and inflammatory events that weakens and kills vital motor neurons in the brain and spinal cord. The process is complex, involving cells that ordinarily protect the neurons from harm.